SRZN · Surrozen, Inc./DE
$23.50
-0.51 (-2.12%)
At close · Aug 20
Market Cap
$274.21M
Shares
11.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.50
Open$24.46
Day$23.09–24.46
52W close$11.10–34.13
Avg vol 30d249K
Short int1.2M · 9.8% float · 4.1d
Short vol62%
Last earningsMar 22, 2023
DataDec 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Dec 14, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+2%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
54%
mid-range
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−15%
trailing
YTD return
+4%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $24 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$6.9M over 90 days · 100% sells
Short interest
Rising
9.79% of float · ▲ +18.5% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
76 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−67%
Y/Y
EPS growth
−49%
Y/Y
Free cash flow
$-30.4M
Balance sheet
$89.2M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+2%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
54%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $23 › 200d $24 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$6.9M over 90 days · 100% sells
Short interest
Rising
9.79% of float · ▲ +18.5% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
76 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $24 · 54%
Range high $34
vs 200-day avg 0%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRZN
this stock
Surrozen, Inc./DE
|
$274.21M | +4.0% | -67.4% | — | 9.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Dec 14, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRZN | -1.0% | +11.1% | -15.5% | +5.8% | +4.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.0% | +7.8% | -26.6% | +3.7% | -7.9% |
Key facts
CIK
1824893
CUSIP
86889P208
13F (30d)
80 filings
77 filers
Visit website
Investor relations